Form 4 for RCEL AVITA Medical, Inc.
Accepted 2026-06-04 19:09:40 ET · period of report 2026-06-03 · accession 0001603289-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-06-04 19:09 | 2025-08-06+ | RCEL | Tarnoff Michael E | Dir | A - Grant | — | +48.5K | 48.5K | New | — |
| DM | 2026-06-04 19:09 | 2025-08-06+ | RCEL | Tarnoff Michael E | Dir | A - Grant | $0.00 | +35.2K | 16.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-06 | A | A | 26,250 | — | 26,250 | D | — | — | (F1) Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. (F2) Includes unvested RSUs |
| 2 | Common | Common Stock | 2026-01-20 | A | A | 22,214 | — | 48,464 | D | — | — | (F3) Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. (F2) Includes unvested RSUs |
| 3 | Derivative | Stock Options (Right to Buy) | 2025-08-06 | A | A | 19,063 | $0.00 | 19,063 | D | $5.36 · — to 2035-08-06 | 19,063 Common Stock | (F4) On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. (F5) These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date. |
| 4 | Derivative | Stock Options (Right to Buy) | 2026-01-20 | A | A | 16,133 | $0.00 | 16,133 | D | $3.77 · 2027-01-20 to 2036-01-20 | 16,133 Common Stock | (F6) On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. |